Author’s response to reviews

Title: Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms

Authors:

Anna Santaella (Anna.Santaella@radboudumc.nl)
H. Kuiperij (Bea.Kuiperij@radboudumc.nl)
Anouke van Rumund (Anouke.vanRumund@radboudumc.nl)
Rianne Esselink (Rianne.Esselink@radboudumc.nl)
Alain van Gool (Alain.vanGool@radboudumc.nl)
Bas Bloem (Bas.Bloem@radboudumc.nl)
Marcel Verbeek (marcel.verbeek@radboudumc.nl)

Version: 2 Date: 28 Nov 2019

Author’s response to reviews:

Dear Editor-in-Chief,

Please find enclosed our revised manuscript entitled “Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms” (manuscript number NURL-D-19-00721).

First of all, we would like to thank you for giving us the opportunity to submit a new revised version of our manuscript to be considered for publication in BMC Neurology. In addition, we would like to thank the reviewers for their critical review and helpful comments. Below we provide a point-by-point response to the reviewer comments, and how we addressed these points in the manuscript. In the enclosed manuscript we used Track Changes to pinpoint the modifications that we made based on the reviewer comments.

Point by point response to the reviewer and editor

Reviewer 2

The authors have answered most of the queries that were raised. However, the methodology of Bonferroni correction or Games Howell post hoc test hat were applied and all the description in the reply for the question 1 should be added in the section of statistical analysis in the manuscript. In addition, since the number of each group was changed in this revision, the details
in the table 1 were supposed to be amended accordingly. For example, the mean age at inclusion, the H-Y stage, the UPDRS part III and MMSE scores in the groups of MSA and PD.

Response: Thanks for your comments. The description of Bonferroni correction and Games Howell post hoc test have been added to the data analysis section of the manuscript.

We would like to apologize if the changes we reported in our first revision (i.e. correction of the numbers in each group) led to confusions. While revising our manuscript, we discovered that the number of patients in each group was not correctly presented (which was corrected in the first revision). However, in the original manuscript (first submission) the other data (e.g. the mean age at inclusion, the H-Y stage, the UPDRS part III and MMSE scores) were already correctly calculated based on the correct number of patients and did not require correction.

Yours sincerely,

Dr. Marcel M. Verbeek

Radboud University Medical Center
Department of neurology, 830 TML
P.O. Box 9101
6500 HB Nijmegen, The Netherlands
Email: Marcel.Verbeek@radboudumc.nl
Tel.: +31243614567